Cerebrospinal fluid levels of amyloid beta 1-43 in patients with amnestic mild cognitive impairment or early Alzheimer’s disease: a 2-year follow-up study

Cerebrospinal fluid levels of amyloid beta 1-43 in patients with amnestic mild cognitive impairment or early Alzheimer’s disease: a 2-year follow-up study

Abstract IntroductionBiomarkers that will reliably predict the onset of Alzheimer’s disease (AD) are urgently needed. Although cerebrospinal fluid (CSF) amyloid beta 1-42 (Aβ42), total tau and phosphorylated tau can be used to complement the clinical diagnosis of AD, amnestic mild cognitive impairme...

Full description

Bibliographic Details
Main Authors: Camilla eLauridsen, Sigrid Botne Sando, Adiba eShabnam, Ina eMøller, Guro eBerge, Gøril Rolfseng Grøntvedt, Inger Johanne Bakken, Øyvind eSalvesen, Geir eBråthen, Linda Rosemary White
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-03-01
Series:Frontiers in Aging Neuroscience
Subjects:
Cerebrospinal Fluid
biomarkers
Alzheimer’s disease
Diagnostic accuracy
amnestic mild cognitive impairment (aMCI)
amyloid beta 1-43
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnagi.2016.00030/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fnagi.2016.00030/full

Similar Items